PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Carpinelli P et al. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3158-68.
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Gontarewicz A et al. Blood. 2008 Apr 15;111(8):4355-64.
PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Soncini C et al. Clin Cancer Res. 2006 Jul 1;12(13):4080-9.
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.